Get the Stockscreener App
5.82
3.00%
-0.18
Exozymes Inc stock is traded at $5.82, with a volume of 9,086.
It is down -3.00% in the last 24 hours and down -16.86% over the past month.
EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods. The company believes its platform will enable scalable production of chemical molecules found in nature in a process that is alternative to and more environmentally friendly and sustainable than the typical methods used today, such as chemical synthesis, natural extraction, and synthetic biology.
See More
Previous Close:
$6.00
Open:
$5.89
24h Volume:
9,086
Relative Volume:
1.02
Market Cap:
$54.02M
Revenue:
$70,100
Net Income/Loss:
$-9.67M
P/E Ratio:
-5.056
EPS:
-1.1511
Net Cash Flow:
$-7.09M
1W Performance:
+14.01%
1M Performance:
-16.86%
6M Performance:
-43.07%
1Y Performance:
-41.74%
1-Day Range:
$5.82
$6.49
1-Week Range:
$5.12
$6.49
52-Week Range:
$4.35
$18.40
Exozymes Inc Stock (EXOZ) Company Profile
Name
Exozymes Inc
Sector
Industry
Phone
(626) - 415 - 1488
Address
750 ROYAL OAKS DR, MONROVIA
Compare EXOZ vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
5.82 | 53.46M | 70,100 | -9.67M | -7.09M | -1.1511 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Exozymes Inc Stock (EXOZ) Latest News
MDB Capital Holdings (MDBH) records $16.1M H1 2026 loss and $33.1M eXoZymes stake - Stock Titan
EXOZYMES INC. 2Q 2026: Revenue $0 Net loss $(5.25M) — 10-Q Summary - TradingView
EXoZymes, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
eXoZymes Inc (EXOZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
eXoZymes Q2 Results: Update call scheduled for August 20 - scanx.trade
eXoZymes CEO to Lead Q2 Results Webinar With Q&A Aug. 20 - Stock Titan
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026 - ACCESS Newswire
eXoZymes Inc. (EXOZ) Climbs 3.92% to $5.3 as Biotech Stock Approaches Key ResistancePut Spread Alert - dars.gov.et
eXoZymes Inc (EXOZ) Stock News Today - TradingKey
eXoZymes Inc. (EXOZ) Slides 5.15% to $4.60 as Traders Eye Key Support at $4.37Turnaround Stocks - dars.gov.et
eXoZymes Inc (EXOZ) Income Statement - TradingKey
eXoZymes Inc (EXOZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
eXoZymes Inc (EXOZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
eXoZymes Inc (EXOZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
eXoZymes Inc (EXOZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
EXOZ|eXoZymes Inc|Price:4.550|Chg%:-0.050 - TradingKey
eXoZymes Inc. Revenue Breakdown – NASDAQ:EXOZ - TradingView
EXOZ|eXoZymes Inc|Price:4.500|Chg%:-0.210 - TradingKey
eXoZymes Inc (EXOZ) Cash Flow - TradingKey
eXoZymes Inc (EXOZ) Balance Sheet - TradingKey
eXoZymes Inc (EXOZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
eXoZymes Inc (EXOZ) Institutional Confidence - TradingKey
eXoZymes Inc. (EXOZ) Slides Amid Biotech Volatility: Key Levels to WatchDay Trade Opportunities - dars.gov.et
eXoZymes, Inc. (EXOZ) Stock Price, News, Quote & History - Yahoo! Finance Canada
exoZymes selected for DOE Genesis Mission AI project By Investing.com - Investing.com Nigeria
exoZymes selected for DOE Genesis Mission AI project - Investing.com
EXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing - marketscreener.com
eXoZymes and Berkeley Lab Develop AI-Powered Digital Twins - Stock Titan
eXoZymes Inc. (EXOZ) Holds Steady Near Support as Trading Volume Remains NormalTotal Put Call - dars.gov.et
eXoZymes (EXOZ) Stock Gains 3.76% as Buyers Hold Above Key SupportGrowth Stock Picks - dars.gov.et
If You Invested $1,000 in Invizyne Technologies Inc (IZTC) - Stock Titan
eXoZymes Inc. (EXOZ) Plunges 12.6%: Key Support Levels Under PressureVolume Nodes - dars.gov.et
Enterprise value to EBITDA forward of eXoZymes Inc. – NASDAQ:EXOZ - TradingView
Price to sales forward of eXoZymes Inc. – NASDAQ:EXOZ - TradingView
Enterprise value to EBIT forward of eXoZymes Inc. – NASDAQ:EXOZ - TradingView
eXoZymes Inc. (EXOZ) Slips 2.96% – Testing Key Support Near $7.17Smart Beta Flow - dars.gov.et
Enterprise value to revenue forward of eXoZymes Inc. – NASDAQ:EXOZ - TradingView
Price to earnings forward of eXoZymes Inc. – NASDAQ:EXOZ - TradingView
eXoZymes Completes New Securities Offering to Fund Pipeline - TipRanks
eXoZymes Raises $0.64 Million Via Unit Offering; Adds MDB Placement Pact and Warrant Coverage - TradingView
eXoZymes (NASDAQ: EXOZ) raises $639K in unit sale with resettable warrants - Stock Titan
Form 424B5 eXoZymes Inc For: 30 June - Investing.com UK
Form 424B5 eXoZymes Inc For: 30 June By Investing.com - Investing.com India
eXoZymes (EXOZ) raises net $565K; warrants exercisable 6/5/2027–2031 - Stock Titan
eXoZymes Secures $2M NIH Grant to Advance AI-Engineered Cannabinoid Analogs for Drug Discovery - Minichart
eXoZymes Secures NIH Grant to Advance Cannabinoid Pipeline - TipRanks
eXoZymes awarded $2.03M NIH SBIR grant to develop cannabinoid analogs - TradingView
eXoZymes (NASDAQ: EXOZ) lands $2,028,518 NIH grant for cannabinoid analog R&D - Stock Titan
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery - The National Law Review
exoZymes receives $2M NIH grant for cannabinoid research - Investing.com
EXoZymes receives $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery - marketscreener.com
Exozymes Inc Stock (EXOZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):